Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Uterine Cervical Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 4 Carcinoma, Renal Cell 4 Advanced Solid Tumors 4 Urinary Bladder Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Melanoma 3 Lung Neoplasms 3 Solid Tumor 2 Ovarian Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Kidney Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumors 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1

Interventions

Carboplatin 19 Pemetrexed 10 Paclitaxel 7 pembrolizumab 5 Nivolumab 5 Cisplatin 5 Gemcitabine 4 osimertinib 3 entinostat 3 camrelizumab 3 atezolizumab 3 Erlotinib Hydrochloride 3 zipalertinib 2 selpercatinib 2 pralsetinib 2 durvalumab 2 apatinib 2 Vinorelbine 2 Surveys and Questionnaires 2 One-Lung Ventilation 2 Ipilimumab 2 Docetaxel 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 zimberelimab 1 toripalimab 1 spartalizumab 1 sotorasib 1 sitravatinib 1 sintilimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Diseases × zimberelimab × Clear all

NCT06431633 2026-05-18

ARIAN

Fundación GECP

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡